Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity

Int J Tuberc Lung Dis. 2014 Mar;18(3):312-4. doi: 10.5588/ijtld.13.0505.

Abstract

Isoniazid preventive therapy (IPT) with antiretroviral therapy (ART) reduces incident tuberculosis among patients infected with the human immunodeficiency virus. We describe IPT use among patients on ART at two primary care clinics in South Africa. Of 597 participants interviewed, 100 (16.8%) reported IPT use; 73.4% (365/497) with no reported IPT use were eligible for IPT. IPT use was associated with age <35 years (aOR 1.90, 95%CI 1.18-3.06), and receiving care at one clinic as opposed to the other (aOR 4.72, 95%CI 2.69-7.93). The high proportion of patients on ART eligible for IPT represents a missed opportunity for IPT scale-up.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antitubercular Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Chi-Square Distribution
  • Coinfection
  • Delivery of Health Care*
  • Female
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • Humans
  • Incidence
  • Isoniazid / therapeutic use*
  • Logistic Models
  • Male
  • Multivariate Analysis
  • Odds Ratio
  • Primary Health Care
  • Prospective Studies
  • South Africa / epidemiology
  • Tuberculosis / diagnosis
  • Tuberculosis / epidemiology
  • Tuberculosis / prevention & control*

Substances

  • Anti-HIV Agents
  • Antitubercular Agents
  • Isoniazid